HK1110205A1 - Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration - Google Patents

Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration

Info

Publication number
HK1110205A1
HK1110205A1 HK08100739.8A HK08100739A HK1110205A1 HK 1110205 A1 HK1110205 A1 HK 1110205A1 HK 08100739 A HK08100739 A HK 08100739A HK 1110205 A1 HK1110205 A1 HK 1110205A1
Authority
HK
Hong Kong
Prior art keywords
administration
producing
nucleic acid
active ingredients
multiparticulate
Prior art date
Application number
HK08100739.8A
Other languages
English (en)
Inventor
Rosario Lizio
Petereit H Hans-Ulrich
Dave Trupti
Michael Gottschalk
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of HK1110205A1 publication Critical patent/HK1110205A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08100739.8A 2004-12-10 2008-01-21 Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration HK1110205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004059792A DE102004059792A1 (de) 2004-12-10 2004-12-10 Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
PCT/EP2005/011864 WO2006061069A1 (de) 2004-12-10 2005-11-05 Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte nukleinsäure-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform

Publications (1)

Publication Number Publication Date
HK1110205A1 true HK1110205A1 (en) 2008-07-11

Family

ID=35709359

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100739.8A HK1110205A1 (en) 2004-12-10 2008-01-21 Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration

Country Status (17)

Country Link
US (1) US8568778B2 (zh)
EP (1) EP1824457B1 (zh)
JP (1) JP5578764B2 (zh)
KR (1) KR101319773B1 (zh)
CN (1) CN101060835B (zh)
BR (1) BRPI0515815B8 (zh)
CA (1) CA2586597C (zh)
DE (1) DE102004059792A1 (zh)
ES (1) ES2569354T3 (zh)
HK (1) HK1110205A1 (zh)
HU (1) HUE028793T2 (zh)
IL (1) IL183753A (zh)
MX (1) MX2007006343A (zh)
PL (1) PL1824457T3 (zh)
SI (1) SI1824457T1 (zh)
TW (1) TW200635617A (zh)
WO (1) WO2006061069A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
RU2009102262A (ru) * 2006-06-26 2010-08-10 Мьючуал Фармасьютикал Компани, Инк. (Us) Композиции активного агента, способы их получения и способы применения
EP2164475A2 (en) * 2007-07-16 2010-03-24 NorthEastern University Therapeutic stable nanoparticles
DE102008048729A1 (de) * 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20130064896A1 (en) * 2009-12-29 2013-03-14 Laman Lynn Alani Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer
BR112012021445B8 (pt) 2010-02-25 2022-07-05 Evonik Roehm Gmbh formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
CN102250878B (zh) * 2011-06-03 2013-01-23 吉林大学 一种基于固相介质表面电荷的反转提取dna的方法
US9107851B2 (en) * 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
CN110603057A (zh) * 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
AU2019275409A1 (en) 2018-05-24 2020-07-16 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
DE102020002360A1 (de) * 2020-04-18 2021-10-21 Friedrich-Schiller-Universität Jena Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW209174B (zh) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE69634697T2 (de) 1995-10-25 2006-05-04 Octoplus B.V. Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6730735B2 (en) 1997-07-03 2004-05-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Conjugate of polyethylene glycol and chitosan
CA2378265C (en) * 1999-08-09 2007-11-20 Dainippon Pharmaceutical Co., Ltd. Solid preparations containing chitosan powder and process for producing the same
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht

Also Published As

Publication number Publication date
KR20070085894A (ko) 2007-08-27
CN101060835A (zh) 2007-10-24
PL1824457T3 (pl) 2016-07-29
US20090280183A1 (en) 2009-11-12
ES2569354T3 (es) 2016-05-10
DE102004059792A1 (de) 2006-06-14
BRPI0515815A (pt) 2008-08-05
EP1824457A1 (de) 2007-08-29
IL183753A0 (en) 2007-09-20
BRPI0515815B1 (pt) 2019-02-05
CA2586597A1 (en) 2006-06-15
US8568778B2 (en) 2013-10-29
JP5578764B2 (ja) 2014-08-27
CA2586597C (en) 2013-09-10
TW200635617A (en) 2006-10-16
CN101060835B (zh) 2013-01-02
IL183753A (en) 2016-12-29
MX2007006343A (es) 2007-07-04
WO2006061069A1 (de) 2006-06-15
KR101319773B1 (ko) 2013-10-17
EP1824457B1 (de) 2016-02-17
JP2008522989A (ja) 2008-07-03
HUE028793T2 (hu) 2017-01-30
BRPI0515815B8 (pt) 2021-05-25
SI1824457T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
HK1110205A1 (en) Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration
GB0412974D0 (en) Method of applying active ingredients
IL169886A0 (en) Method for producing an immediately decomposing oral form of administration which releases active ingredients
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HK1087015A1 (en) Composition comprising a mixture of active principles, and method of preparation
PL1740156T3 (pl) Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
EP1735010A4 (en) METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
PL378065A1 (pl) Podstawione związki N-aryloheterocykliczne, sposób ich wytwarzania oraz ich zastosowanie jako środków leczniczych
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
HK1107271A1 (en) Method of enhancing absorptions of transmucosal administration formulations
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
WO2006001866A3 (en) Crystalline forms of n-desmethylclozapine
WO2005107753A3 (en) Naltrexone long acting formulations and methods of use
EP1809307A4 (en) MEDICAL SOLUTION, PROCESS FOR THEIR MANUFACTURE AND USE
TWI341219B (en) Catalyst for producing methacrylic acid and preparation method thereof
IL184094A0 (en) Novel galenic system for active principle transport, preparation method and use
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
MXPA03006154A (es) Metodo de fabricacion de vacuna combinada.
EP1704135A4 (en) PROPOFOL ANALOGS, PROCESS FOR PREPARING THE SAME, AND METHODS OF USING SAME
AU2003288051A8 (en) Formulations comprising vitamin b12, method of production and use thereof
PL376122A1 (pl) Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki
EP1842548A4 (en) ANTI-HIV MEDIUM, THIS PRESENT POLYPEPTIDE, POLYPEPTIDE ENCODING GENE AND PROCESS FOR PREPARING THE ANTI-HIV MEDIUM
IL169687A0 (en) Methods for the drug prophylaxis of poisoning by cholinesterase inhibitors, and active ingredients and medicaments suitable therefore